Q3 2024 SCHOTT Pharma AG & Co KgaA Earnings Call Transcript
Key Points
- Schott Pharma AG & CO KGaA (WBO:1SXP) reported a 21% year-over-year revenue growth in the third quarter, reaching EUR268 million at constant currencies.
- The company achieved a significant increase in profitability, with an EBITDA margin of 28.2%, up by more than 3 percentage points year-over-year.
- The company's HVS (High Value Solutions) revenue share reached 53% in the first nine months, aligning well with its midterm goal of over 60%.
- Schott Pharma raised its full-year revenue growth guidance from 9%-11% to 11%-13%, reflecting strong performance and market demand.
- The company is actively expanding its production capacities, with new facilities in Hungary and Germany, and a planned USD371 million investment in a new facility in the US to meet growing demand.
- The company anticipates a seasonally weaker fourth quarter due to the annual summer break, which may impact revenue growth and margins.
- There is ongoing underutilization in certain production areas, such as vials, which the company is working to address.
- Currency fluctuations have impacted reported sales growth, with a noted 6% negative impact from currency effects in the first nine months.
- The company faces ramp-up costs associated with expanding production capacities, which could affect short-term profitability.
- The market for GLP-1 therapies and mRNA treatments is still evolving, presenting uncertainties in demand and competitive dynamics.
Good morning, ladies and gentlemen, and welcome to the SCHOTT Pharma conference call for the nine months 2023, 2024. (Operator Instructions) Let me now turn the floor over to your host, Jasko Terzic.
Hello, everyone, and thank you for joining SCHOTT Pharma's earnings call for the third quarter of fiscal year 2024. My name is Jasko Terzic, Senior Manager, Investor Relations, and I will be the host of our call today. With me today our CEO, Andreas Reisse, who joined us remotely, Our CFO, Dr. Almuth Steinkuhler, and Tobias Erfurth, our new Head of Investor Relations, who joined us only two weeks ago.
Andreas will start today's call by providing an update on SCHOTT pharma strategy and business development and the third quartering of fiscal 2024. Followed by Almuth, who will take us through our financials for the period. Finally, Andreas will conclude the presentation before we start the Q&A session.
Before we begin, I would like to direct your attention to our disclaimer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
